Journal
MEDICINAL RESEARCH REVIEWS
Volume 29, Issue 2, Pages 369-393Publisher
WILEY
DOI: 10.1002/med.20138
Keywords
HIV entry inhibitors; attachment inhibitors; co-receptor binding inhibitors; fusion inhibitors; maraviroc (MVC; UK-427,857); enfuvirtide (T20; fuzeon); bevirimat (DSB; PA-457)
Categories
Funding
- National Institute of Allergies and Infectious Diseases [AI-077417, AI-33066]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI077417, R01AI033066] Funding Source: NIH RePORTER
Ask authors/readers for more resources
This review discusses recent progress in the development of anti-HIV agents targeting the viral entry process. The three main classes (attachment inhibitors, co-receptor binding inhibitors, and fusion inhibitors) Lire further broken clown by specific mechanism of action and structure. Many of these inhibitors are in advanced clinical trials, including the HIV Maturation inhibitor bevirimat, from the authors' laboratories. In addition, the CCR5 inhibitor maraviroc has recently been FDA-approved. Possible roles for these agents in anti-HIV therapy, including treatment of virus resistant to current drugs, are also discussed. (C) 2008 Wiley Periodicals, Inc. Med Res Rev, 29, No. 2, 369-393, 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available